Abstract
Our understanding of the molecular pathology of lung cancer is advancing rapidly with several specific genes and chromosomal regions being identified. Lung cancer appears to require many mutations in both dominant and recessive oncogenes to possess malignant phenotypes. Several genetic and epigenetic changes are common to all lung cancer histologic types, while others appear to be cell type specific. However, specific roles of the genes undergoing mutations and the order of cumulative molecular changes that lead to the development of each lung tumor histologic type remain to be fully elucidated. Recent findings of molecular abnormalities in normal appearing and preneoplastic bronchial epithelium from patients with lung cancer and chronic smokers suggest that genetic changes may serve as biomarkers for early diagnosis, risk assessment and monitoring response to chemoprevention.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, Esteller M, Herman JG, Wu L, Decker PA, Jen J, Sidransky D . 1999 J. Natl. Cancer Inst. 91: 332–339
Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG . 2001 Hum. Mol. Genet. 10: 687–692
Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG . 1998 Proc. Natl. Acad. Sci. USA 95: 11891–11896
Betticher DC, Heighway J, Thatcher N, Hasleton PS . 1997 Br. J. Cancer 75: 1761–1768
Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD . 2001 J. Natl. Cancer Inst. 93: 691–699
Colby TV, Wistuba II, Gazdar A . 1998 Adv. Anat. Pathol. 5: 205–215
Esteller M, Corn PG, Baylin SB, Herman JG . 2001 Cancer Res. 61: 3225–3229
Franklin WA, Gazdar AF, Haney J, Wistuba II, La Rosa FG, Kennedy T, Ritchey DM, Miller YE . 1997 J. Clin. Invest. 100: 2133–2137
Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD . 2000 Cancer Res. 60: 4894–4906
Greenlee RT, Hill-Harmon MB, Murray T, Thun M . 2001 CA Cancer J. Clin. 51: 15–36
Hanahan D . 2000 Nature 406: 573–574
Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC . 1990 Nature 346: 866–868
Hittelman WN (ed) . 1999 Molecular pathology of early cancer Srivastava S, Gazdar AF and Henson DE (eds) The Netherlands: IOS Press: Van Demanstratt pp. 385–404
Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar AF, Piatyszek MA, Shay JW . 1995 J. Natl. Cancer Inst. 87: 895–902
Hung J, Kishimoto Y, Sugio K, Virmani A, McIntire DD, Minna JD, Gazdar AF . 1995 JAMA 273: 558–563
Kersting M, Friedl C, Kraus A, Behn M, Pankow W, Schuermann M . 2000 J. Clin. Oncol. 18: 3221–3229
Kishimoto Y, Sugio K, Mitsudomi T, Oyama T, Virmani A, McIntire DD, Gazdar AF . 1995 J. Natl. Cancer Inst. 87: 1224–1229
Kitamura H, Kameda Y, Ito T, Hayashi H . 1999 Am. J. Clin. Pathol. 111: 610–622
Knudson AG . 1989 Cancer 63: 1888–1891
Lam S, LeRiche JC, Zheng Y, Coldman A, MacAulay C, Hawk E, Kellof G, Gazdar AF . 1999 J. Natl. Cancer Inst. 91: 691–696
Lang SM, Stratakis DF, Freudling A, Ebelt K, Oduncu F, Hautmann H, Huber RM . 2000 Eur. J. Med. Res. 5: 341–346
Lee JJ, Liu D, Lee JS, Kurie JM, Khuri FR, Ibarguen H, Morice RC, Walsh G, Ro JY, Broxson A, Hong WK, Hittelman WN . 2001 J. Natl. Cancer Inst. 93: 1081–1088
Mao L, Hruban RH, Boyle JO, Tockman M, Sidransky D . 1994 Cancer Res. 54: 1634–1637
Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, Ro JY, Broxson A, Yu R, Morice RC, Kemp BL, Khuri FR, Walsh GL, Hittelman WN, Hong WK . 1997 J. Natl. Cancer Inst. 89: 857–862
Mills NE, Fishman CL, Scholes J, Anderson SE, Rom WN, Jacobson DR . 1995 J. Natl. Cancer Inst. 87: 1056–1060
Morin GB . 1989 Cell 59: 521–529
Nuorva K, Soini Y, Kamel D, Autio-Harmainen H, Risteli L, Risteli J, Vahakangas K, Paakko P . 1993 Am. J. Pathol. 142: 725–732
Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA . 2000 Cancer Res. 60: 5954–5958
Park IW, Wistuba II, Maitra A, Milchgrub S, Virmani AK, Minna JD, Gazdar AF . 1999 J. Natl. Cancer Inst. 91: 1863–1868
Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R . 2000 BMJ 321: 323–329
Sekido Y, Fong KM, Minna JD . 1998 Biochim. Biophys. Acta 1378: F21–F59
Shivapurkar N, Virmani AK, Wistuba II, Milchgrub S, Mackay B, Minna JD, Gazdar AF . 1999 Clin. Cancer Res. 5: 17–23
Smith AL, Hung J, Walker L, Rogers TE, Vuitch F, Lee E, Gazdar AF . 1996 Br. J. Cancer 73: 203–209
Soria JC, Moon C, Wang L, Hittelman WN, Jang SJ, Sun SY, Lee JJ, Liu D, Kurie JM, Morice RC, Lee JS, Hong WK, Mao L . 2001 J. Natl. Cancer Inst. 93: 1257–1263
Soria JC, Rodriguez M, Liu DD, Lee JJ, Hong WK, Mao L . 2002 Cancer Res. 62: 351–355
Sundaresan V, Ganly P, Hasleton P, Rudd R, Sinha G, Bleehen NM, Rabbitts P . 1992 Oncogene 7: 1989–1997
Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, Harada K, Takahashi T, Sugio K, Brambilla E, Gilcrease M, Minna JD, Gazdar AF . 2001 Molecular Cancer Therapeutics 1: 61–67
Viallet J, Sausville EA . 1996 J. Cell Biochem. Suppl. 24: 228–236
Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, Tonk V, Minna JD, Gazdar AF . 1998 Genes Chromosomes Cancer 21: 308–319
Virmani AK, Rahti A, Zöchbauer-Müller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF . 2000 J. Natl. Cancer Inst. 92: 1303–1307
Westra WH, Slebos RJ, Offerhaus GJ, Goodman SN, Evers SG, Kensler TW, Askin FB, Rodenhuis S, Hruban RH . 1993 Cancer 72: 432–438
Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon 3rd JW, Garner HR, McKay B, Latif F, Lerman MI, Lam S, Gazdar AF, Minna JD . 2000a Cancer Res. 60: 1949–1960
Wistuba II, Behrens C, Virmani AK, Milchgrub S, Syed S, Lam S, Mackay B, Minna JD, Gazdar AF . 1999a Cancer Res. 59: 1973–1979
Wistuba II, Berry J, Behrens C, Maitra A, Shivapurkar N, Milchgrub S, Mackay B, Minna JD, Gazdar AF . 2000b Clin. Cancer Res. 6: 2604–2610
Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD, Gazdar AF . 1999b Oncogene 18: 643–650
Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, LeRiche J, Samet JM, Srivastava S, Minna JD, Gazdar AF . 1997 J. Natl. Cancer Inst. 89: 1366–1373
Yashima K, Litzky LA, Kaiser L, Rogers T, Lam S, Wistuba II, Milchgrub S, Srivastava S, Piatyszek MA, Shay JW, Gazdar AF . 1997 Cancer Res. 57: 2373–2377
Zochbauer-Muller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF, Minna JD . 2001a Cancer Res. 61: 3581–3585
Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD . 2001b Cancer Res. 61: 249–255
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wistuba, I., Mao, L. & Gazdar, A. Smoking molecular damage in bronchial epithelium. Oncogene 21, 7298–7306 (2002). https://doi.org/10.1038/sj.onc.1205806
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205806
Keywords
This article is cited by
-
Analytical validation of the Percepta genomic sequencing classifier; an RNA next generation sequencing assay for the assessment of Lung Cancer risk of suspicious pulmonary nodules
BMC Cancer (2021)
-
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response
British Journal of Cancer (2021)
-
Timing somatic events in the evolution of cancer
Genome Biology (2018)
-
Airway brushing as a new experimental methodology to detect airway gene expression signatures in mouse lung squamous cell carcinoma
Scientific Reports (2018)
-
Analytical performance of a bronchial genomic classifier
BMC Cancer (2016)